(C) 2010 Published by Elsevier Masson SAS.”
“A targeted oral drug delivery system is useful to improve the treatment of gastrointestinal diseases. A high density sinking dosage form can sink to the bottom of the stomach near the pylori sections to enhance gastric retention. However, it is difficult to achieve a high

Bcl-2 cancer density sinking system using the traditional technology. In the current study, novel stomach-specific sinking magnetic microparticles (SMMPs) were prepared via the monoaxial electrospray method for enhanced gastric antimicrobial delivery. The size of SMMPs was approximately 5 mu m, and the Fe3O4 nanoparticles were observed in the SMMPs by transmission electron microscopy (TEM). The density of SMMPs increased as the concentration of Fe3O4 nanoparticles in the electrospray inlet flow increased, with ALK activation the maximum true density of approximately 3.52 g/cm(3). The SMMPs displayed strong magnetism in vitro and in vivo. They can settle down in water within 120 s in vitro, and the settling time decreased to 20 s under a magnetic field. Furthermore, an in vivo gamma scintigraphy study demonstrated that I-131 labeled SMMPs were retained in the stomach for over 8 h, and an external permanent magnet can increase their gastric retention time even further. Using Helicobacter pylori as a model bacterium, amoxicillin-loaded SMMPs

exhibited a significantly greater eradication of H. pylon compared to the free drug, in vivo. Our results suggested that electrospray is an effective technique to prepare the high density gastroretentive dosage forms. We have shown that stomach-specific SMMPs can supply better treatment for H. pylori infections and have the potential to be used in clinical practice.”
“Introns can enhance gene expression levels. This effect is known as intron-mediated

enhancement, which is different from that Pfizer Licensed Compound Library clinical trial of enhancers or promoters. In our previous study, under the control of the cytomegalovirus or goat beta-casein promoter, the vector containing intron V-TPOcDNA expressed the highest thrombopoietin (TPO) level, whereas the vector containing TPOgDNA expressed the lowest level. In order to verify whether intron V also improves TPO expression in the milk of transgenic mice, rat whey acidic protein promoter was used as regulatory element to construct mammary gland expression vectors including pTPOWA (containing TPOcDNA), pTPOWB (containing intron V-TPOcDNA), and pTPOWC (containing TPOgDNA). These vectors were transfected into HC-11 cells and the supernatants were analyzed at 48 h. The highest TPO level was found in pTPOWB (795 pg/mL) and the lowest level in pTPOWC (193 pg/mL). Then, corresponding vectors were microinjected into fertilized mice zygotes. Transgenic mice were identified by polymerase chain reaction and Southern blot.